Department of Pediatric Infectious Disease, Gazi University, Faculty of Medicine, Ankara, Turkey.
Expert Rev Anti Infect Ther. 2011 Mar;9(3):339-46. doi: 10.1586/eri.11.7.
Cases of invasive fungal infections are increasing globally due to an increase in the immunosuppressed population, the use of broad-spectrum antibiotics and the invasive instrumentation of patients in intensive care units. Ongoing emergence of resistance and problems with toxicity have resulted in the need for the development of new antifungal agents. Anidulafungin, the most recently developed echinocandin, is approved by the US FDA for treatment of candidemia, other forms of Candida infection and esophageal candidiasis in non-neutropenic adult patients, but it is not currently licensed for pediatric usage. The drug is projected to be distinctive owing to its unique pharmacokinetics and is already listed in adult antifungal treatment guidelines. In this article, anidulafungin will be reviewed with a focus on pediatric patients.
由于免疫抑制人群增加、广谱抗生素的使用以及重症监护病房患者的侵入性操作，全球侵袭性真菌感染的病例正在增加。由于耐药性的不断出现和毒性问题，需要开发新的抗真菌药物。阿尼达fungin 是最近开发的一种棘白菌素，已被美国 FDA 批准用于治疗中性粒细胞减少症成年患者的念珠菌血症、其他形式的念珠菌感染和食管念珠菌病，但目前尚未获准用于儿科。该药预计因其独特的药代动力学而具有独特性，已被列入成人抗真菌治疗指南。本文将重点讨论儿科患者，对阿尼达fungin 进行综述。
